thedxwire.bsky.social

84.4% and Counting Earnings week opens with MRD receipts in hand.

Earnings week preview: Danaher tomorrow, then TMO & Roche Wednesday. Plus: 10x Genomics announces CLIA lab plans -spatial biology coming to the clinic. #MolDx #Diagnostics 👇
substack.com/@thedxwire/n...

CDx Market Heats Up Oncology CDx market projected to $12.84B by 2035 • Danaher, Thermo Fisher, Roche all report this week • FDA comment period closes in 6 days

Oncology CDx market projected to hit $12.84B by 2035 as FDA reclassification proposal gains momentum. Earnings week ahead: Danaher, Thermo Fisher, Roche all report. #MolDx #Diagnostics

open.substack.com/pub/thedxwir...

CDx Market Heats Up Oncology CDx market projected to $12.84B by 2035 • Danaher, Thermo Fisher, Roche all report this week • FDA comment period closes in 6 days

Oncology CDx market projected to hit $12.84B by 2035 as FDA reclassification proposal gains momentum. Earnings week
ahead: Danaher, Thermo Fisher, Roche all report. #MolDx #Diagnostics

open.substack.com/pub/thedxwir...

Leadership Shuffle at NeoGenomics, BLOODPAC Sets MRD Standards Thermo Fisher Asheville closure affects 421 • RNA-seq shows 87% actionable rate in Nature Medicine • SBIR/STTR Jan 30 deadline looms

NeoGenomics hits $727M revenue milestone • FoundationOne CDx approved for entrectinib • Goldman flips Roche to
Neutral ahead of results
open.substack.com/pub/thedxwir...

Natera-NVIDIA Partnership Signals AI-First Future for Precision Dx NeoGenomics RaDaR ST ready for market • Guardant Shield driving 335% volume growth • Thermo Fisher at 52-week hig

Natera taps NVIDIA to train AI foundation models at "unprecedented scale" - 75% faster genomic analysis, 45% faster
model training. The AI-diagnostics convergence is accelerating. #MolDx #PrecisionMedicine👇
open.substack.com/pub/thedxwir...

JPM Day 3: MRD Takes Center Stage First ctDNA MRD in NCCN guidelines, JPM Day 3 coverage, $4B SBIR (still) frozen

Liquid biopsy MRD just went from "promising" to "guideline-recommended."

NCCN inclusion is the signal. The rest is execution.

Full breakdown in today's DxWire 👇
open.substack.com/pub/thedxwir...

Illumina's Cell Atlas & Samsung's Cancer Bet Lead JPM Abbott-Exact merger vote locked in; $21B deal heads to shareholders

Illumina just unveiled the world's largest functional cell dictionary: 1B cells × 20K genes × CRISPR. Samsung Biologics signals Plant 6 + Bio Campus 3 in 2026. JPM26 is delivering. 👇
open.substack.com/pub/thedxwir...

JPM Week Kicks Off as CDx Reclassification Clock Ticks Handshakes at the Westin, deadlines at the FDA.

open.substack.com/pub/thedxwir...

JPM kicks off, FDA's CDx reclassification clock ticks (14 days left), liquid biopsy snapshot, and $152B IVD market projections👇

JPM 2026 Kicks Off as FDA Backlog Concerns Loom MSK's nanosensor liquid biopsy hits 98% accuracy; SAGA data shows 42% of MRD positives missed by standard ctDNA

JPM 2026 kicks off today.

Meanwhile: FDA backlogs loom, MSK drops a 98% accurate brain tumor liquid biopsy, and SAGA data shows 42% of MRD-positive patients missed by standard ctDNA. 👇

open.substack.com/pub/thedxwir...

The Great Unbundling (?) Thermo Fisher weighs $4B diagnostics exit as MRD momentum builds into JPM week

Thermo Fisher exploring USD 4B+ diagnostics divestiture…

open.substack.com/pub/thedxwir...

Dx Stocks Rally Guardant Health and Thermo Fisher hit 52-week high, CDMRP faces 57% budget cut

Molecular diagnostics stocks are having a moment.

open.substack.com/pub/thedxwir...

First Biotech IPO of 2026: Aktis Aims for $182M+ Plus FDA softens AI/digital health oversight, OraSure files first molecular STI self-test, and Natera's ALTAIR delivers

Ahead of the J.P. Morgan Healthcare Conference, Aktis Oncology (AKTS) could be 2026's first biotech IPO — raising $182M+. More 👇

open.substack.com/pub/thedxwir...

Why I'm Building The Dx Wire bioMerieux, BIOSECURE, and the SBIR freeze

Why I'm Building The Dx Wire
open.substack.com/pub/thedxwir...